Option chain shows key data for Metagenomi's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Metagenomi.

Metagenomi (NASDAQ:MGX) Stock, Option Chain

Metagenomi

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).

Insights From Analysts

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BLMN

CCOI

CRWD

GNSS

PANW

PGNY

SNOW

Cogent Communications To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday

Moderna_COVID-19_vaccine_(2021)_G

Biotech

Earnings

Large Cap

Guidance

Health Care

Movers

General

MRNA

Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance reaffirms $4 billion sales target for 2024.

Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars

Metagenomi Inc

MGX Minerals Inc

Raymond James analyst Steve Hansen upgrades Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) from Market Perform to Outperform and raises the price target from $58 to $60.

Upgrades

Raymond James Upgrades Nutrien to Outperform, Raises Price Target to $60

Warrior Met Coal's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCC#NYSE">HCC</a>) short percent of float has risen 14.86% since its last report. The company recently reported that it has 5.26 million shares sold short, which is 13.99% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.83 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Warrior Met Coal Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733247024_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Warrior Met Coal has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Warrior Met Coal's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Warrior Met Coal's peer group average for short interest as a percentage of float is 3.96%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(HCC) - Analyzing Warrior Met Coal's Short Interest

PENN Entertainment's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NYSE">PENN</a>) short percent of float has fallen 7.46% since its last report. The company recently reported that it has 18.40 million shares sold short, which is 13.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>PENN Entertainment Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733247019_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for PENN Entertainment has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing PENN Entertainment's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PENN Entertainment's peer group average for short interest as a percentage of float is 4.57%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

PENN

How Is The Market Feeling About PENN Entertainment?

Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) shares jumped <a href="https://www.benzinga.com/quote/CRDO">almost 40% in early trading on Tuesday</a>.
The visibility into the company's growth inflection in the back half of the year improved significantly, according to BofA Securities.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58a5e02943eaaa00018d9399/vivek-arya">Analyst Vivek Arya</a> upgraded the rating for Credo Technology from Underperform to Buy while raising the price target from $27 to $80.
The Credo Technology Thesis: The company delivered a "solid beat and material raise" quarter, Arya said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Credo Technology's outlook suggests "the start of a multi-year adoption cycle for its Active Electrical Cable (AEC) product that enables power-efficient AI clusters," he added.
The company's earnings call addressed the concerns around the market for AEC, "with 3x 10% customers," including Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) as well as "growing momentum in other adjacent areas (optical DSP, line card PHY, retimer)," the analyst stated.
Credo Technology is likely to generate robust results in the back half of fiscal 2025, "driven by strong AI growth at Amazon Web Services, a key customer (and investor)," he further wrote.
CRDO Price Action: Shares of Credo Technology had risen by 49.24% to $71.34 at the time of publication on Tuesday.
Read More: • <a href="https://www.benzinga.com/24/12/42284734/why-credo-technology-group-shares-are-trading-higher-by-40-here-are-20-stocks-moving-premarket">Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket</a>
Photo: Courtesy Credo

Analyst Color

Long Ideas

Tech

AMZN

CRDO

MSFT

TSLA

Credo Technology Analyst Double Upgrades AI Play, Raises Forecast By Almost 200%

Insmed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NYSE">INSM</a>) short percent of float has fallen 12.63% since its last report. The company recently reported that it has 12.10 million shares sold short, which is 6.85% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insmed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733247013_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insmed has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Insmed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insmed's peer group average for short interest as a percentage of float is 4.93%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

INSM

How Is The Market Feeling About Insmed?

Needham analyst Mike Matson reiterates Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Buy and maintains $112 price target.

Reiteration

Needham Reiterates Buy on Haemonetics, Maintains $112 Price Target

<a href="https://www.foxbusiness.com/video/5640669329001" title="https://www.foxbusiness.com/video/5640669329001">https://www.foxbusiness.com/video/5640669329001</a>

Macro Economic Events

Economics

Federal Reserve

Fed's Daly Says Neutral Rate Is Closer To 3%; We Can Take Our Time Getting To Neutral; We Will Continue To Have Restrictive Policy Until Inflation Gets To 2%; Don't See Any Reason For A Rate Hike; Trajectory Of Change Is Down

Amazon Aurora DSQL provides a distributed SQL database with 99.999% multi-Region availability, virtually unlimited scalability, strong consistency, and zero infrastructure management

AWS Announces New Database Capabilities Including Amazon Aurora DSQL

Fed's Daly Says Employers Are Filling Positions For Core Work, But Not Taking A Lot Of Risk

Fed's Daly Says Even If We Do Another Rate Cut, Policy Will Remain Restrictive; Trade Issues Don't Usually Derail Growth, Economy Adjusts; We Are Prepared To Assess Things, But Need To See Policies Before Fed Reacts

Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares are trading higher Tuesday following the company's announcement that it acquired real estate for seven of its core metal recycling facilities, a move expected to enhance its financial and strategic position. Here&#8217;s <a href="https://www.benzinga.com/quote/GWAV">what you need to know.</a>
What To Know: The acquisition was completed through a purchase from the company&#8217;s CEO Danny Meeks. The strategic initiative is expected to eliminate $1.7 million in annual rent expenses, substantially improve Greenwave&#8217;s cash flow and reduce operating costs, providing the company with more financial flexibility.
The acquired facilities are spread across critical locations in Virginia including Norfolk, Virginia Beach and Portsmouth. The sites are strategically important due to their proximity to major infrastructure, including the largest U.S. Naval Base in Norfolk and the Port of Virginia in Portsmouth.
Additionally, the facilities benefit from grandfathered operational licenses that create high barriers to entry in the tightly regulated metal recycling industry, further strengthening Greenwave's competitive advantage.
Greenwave operates 13 metal recycling facilities across Virginia, North Carolina and Ohio, supplying steel mills and industrial companies with ferrous and non-ferrous metals. The company&#8217;s operations play a vital role in the recycling supply chain, contributing raw materials for critical infrastructure and national security projects, including U.S. warships. 
GWAV Price Action: Greenwave Technology Solutions shares were up 47% at 53 cents at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1733167806337199"><img loading="lazy" decoding="async" width="1024" height="545" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03113544/GWAV-1024x545.png" alt="" class="wp-image-674878" style="width:434px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03113544/GWAV-1024x545.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03113544/GWAV-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03113544/GWAV-768x409.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03113544/GWAV.png 1162w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42296197/ondo-finance-ethereums-blackrock-backed-tokenization-crypto-surges-38-why-is-ondo-going-up">Ondo Finance, Ethereum&#8217;s BlackRock-Backed Tokenization Crypto, Surges 38%: Why Is ONDO Going Up?</a></li>
</ul>
Image via Shutterstock.

GWAV

What's Going On With Greenwave Technology Solutions Stock Today?

Fed's Daly In Fox Business Network Interview Says Us Economy Is In A Really Good Place; December Rate Cut Is Absolutely Not Off The Table; Timing Of Rate Cut Is Up For Debate, But Need To Keep Moving Policy Rate Down; We Need An Open Mind;  Labor Market Is Completely In Balance, Not A Source Of Inflation; We Knew Inflation Woul Be A Bumpy Ride, It Is Moving Down Gradually, But More Work To Do

WIIM

Lion Electric shares are trading higher. The company recently announced amendments to senior credit instruments and workforce reductions.

Leerink Partners analyst Jeffrey La Rosa maintains Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) with a Outperform and raises the price target from $79 to $91.

JANX

Leerink Partners Maintains Outperform on Janux Therapeutics, Raises Price Target to $91

FromSoftware's award-winning Elden Ring is a franchise fans won't need to say goodbye to just yet, but don't expect a <a href="https://www.benzinga.com/general/gaming">direct sequel.</a>
In a recent <a href="https://game.watch.impress.co.jp/docs/interview/1644616.html">interview</a> with Japanese outlet Game Watch, Hidetaka Miyazaki, the studio&#8217;s acclaimed creator, confirmed that Elden Ring 2 is not part of the company&#8217;s plans.
See Also:<a href="https://www.benzinga.com/general/gaming/24/12/42270630/gta-6-fans-analyze-playlists-and-combat-ai-chaos-one-year-after-first-trailer"> GTA 6 Fans Analyze Playlists And Combat AI Chaos, One Year After First Trailer</a>
Speaking after Elden Ring DLC Shadow of the Erdtree earned top honors at this year's PlayStation Awards, Miyazaki clarified the studio's direction. 
&#8220;At this point, we are not considering developments such as &#8220;Elden Ring 2&#8221;, he said. &#8220;However, this does not mean that we are denying the development of the IP &#8216;Elden Ring&#8217;.&#8221; 
He added: &#8220;As for &#8216;what will we do then?&#8217;, FromSoftware is running multiple projects as usual. Among them, there are various variations of projects, so I hope you will look forward to them.&#8221;
<h3 class="wp-block-heading">Speculation: What's Next For FromSoftware?</h3>
Beyond Elden Ring, FromSoftware appears to be juggling a slate of unannounced projects. Earlier this year, now-deleted job listings sparked speculation of a potential new Armored Core installment, with mentions of robot characters fueling the theory. Given the studio's legacy in mecha-themed titles, such a pivot would align with its history of alternating between genres.
Moreover, the studio's parent company Kadokawa has acknowledged <a href="https://www.benzinga.com/general/gaming/24/11/42098643/kadokawa-ceo-confirms-sonys-buyout-interest-no-decision-has-been-made">acquisition interest</a> from Sony Group Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>).
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/42141838/elden-ring-creator-hidetaka-miyazaki-teases-various-new-projects-in-development">Elden Ring Creator Hidetaka Miyazaki Teases &#8216;Various New Projects&#8217; In Development</a></li>
</ul>
Image credits: Shutterstock.

Gaming

Sony Group Corporation American Depositary Shares

SONY

'We Are Not Considering Elden Ring 2,' Says FromSoftware's Miyazaki

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) with a Buy and maintains $2 price target.

APTO

HC Wainwright & Co. Reiterates Buy on Aptose Biosciences, Maintains $2 Price Target

At the recent <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets</a> event, industry leaders tackled how stablecoins are reshaping finance, spurring adoption among institutional investors, and addressing operational hurdles in digital markets. The panel, moderated by BlackRock's Kyle Braden, featured Jennifer O'Rourke of DTCC Digital Assets, Chuck Mounts of S&amp;P Global Ratings, and David Alderman of Franklin Templeton, who provided valuable perspectives.
<h4 class="wp-block-heading">Stablecoins: A Bridge To Institutional Participation</h4>
Mounts described stablecoins as a critical link between traditional finance and the digital asset ecosystem. 
"Stablecoins are&#8230; positioned to be the accelerant to the mass adoption for tradfi firms and crypto financial capabilities in the marketplace," he explained. Mounts shared how S&amp;P Global's stablecoin stability assessment tool is helping institutions evaluate the risk of stablecoins losing their peg to fiat currencies, adding a layer of confidence for new entrants to the market.
Mounts emphasized the need for stablecoins to underpin the tokenization of real-world assets, citing the potential for increased liquidity and operational efficiency. "Policy formation is the single most important non-technology catalyst," he added, predicting that stablecoin legislation could be the first crypto-related law passed by the new Congress.
<h4 class="wp-block-heading">Overcoming Liquidity And Settlement Challenges</h4>
O'Rourke highlighted the practical challenges tied to stablecoin adoption, particularly regarding liquidity pools and settlement speed. She explained that tokenized assets offer fast and programmable transactions, but the supporting payment systems often lag. 
"If you're going to buy a tokenized asset&#8230; you need to be able to pay for it as quickly as you want to receive it," O'Rourke stated. Addressing this disparity, she argued, is essential for widespread adoption.
O'Rourke also touched on the fragmented nature of liquidity in digital markets, where isolated pools make seamless transactions difficult. She stressed the importance of standardizing processes to connect these pools, paving the way for a more cohesive digital marketplace.
<h4 class="wp-block-heading">Regulatory Clarity On The Horizon</h4>
Alderman of Franklin Templeton pointed to recent shifts in U.S. regulation as promising for stablecoins and digital assets. "I think a lot of crypto companies that were thinking about leaving the U.S. will stay, just because now it's a more pro-crypto stance," he said. 
Alderman added that regulatory clarity would encourage companies to invest in new technologies and infrastructure, further supporting the adoption of stablecoins.
Mounts agreed, describing the potential for stablecoin legislation to reduce uncertainty and enable financial institutions to participate more actively in the market. He also noted that stablecoins could play a role in dollarizing foreign economies, citing their use in markets like Argentina as an example.
<h4 class="wp-block-heading">Building A Path Forward</h4>
As the discussion wrapped up, panelists agreed that while stablecoins present challenges, their potential to transform finance is undeniable. The ongoing work to address operational hurdles and regulatory ambiguity will lay the groundwork for broader adoption, making stablecoins a cornerstone of future financial systems.
From their use in tokenizing real-world assets to their potential impact on global markets, stablecoins are proving to be a driving force in bringing digital assets into the institutional fold.
Photo by Igor Faun on Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Interview

'Policy Formation Will Be Critical': Experts Weigh In On Stablecoin Adoption

Decibel Cannabis Company Inc. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/DB#TSXV">DB</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/DBCCF#OTCQB">DBCCF</a>) announced Tuesday that it has received final acceptance from the TSX Venture Exchange for its previously announced acquisition of a Canadian licensed producer of cannabis, AgMedica Bioscience Inc.
The acquisition, arranged through an agreement with Callisto Capital Corp. on October 28, 2024, was made in exchange for a <a href="https://www.benzinga.com/markets/cannabis/24/10/41600492/decibel-acquires-agmedica-announces-private-placement-and-third-quarter-guidance">$6.3 million unsecured convertible debenture</a>. As a result of receiving the acceptance, Decibel has completed the conversion of the convertible debenture, pursuant to which it has issued 114.55 million common shares to Callisto.
The conversion of the convertible debenture was conditional upon receipt of final TSXV acceptance for the acquisition of AgMedica pursuant to Exchange Policy 5.3. This policy would have required approval from disinterested shareholders if Callisto became a major controller of the company. However, because the company has finished its recent private funding, Callisto will not control the company after the bond is converted. Therefore, approval from disinterested shareholders is not needed for the conversion.
Read Also: <a href="https://www.benzinga.com/24/12/42272602/cannabis-retail-giant-high-tide-launches-cabana-club-membership-program-in-us-eu-and-uk-with-new-product-categories">Cannabis Giant High Tide Taps Into $113 Billion Global E-Commerce Market With New Product Categories</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
On Nov. 25, the Calgary, Alberta-based cannabis company confirmed completion of the second and final closing of non-brokered private placement of its common shares at $0.06 per share. At the second closing of the offering, it issued 19.65 million shares for gross proceeds of <a href="https://www.benzinga.com/news/financing/24/11/42164794/decibel-cannabis-raises-1-18m-secures-capital-for-agmedica-bioscience-integration">roughly $1.18 million.</a>
Previously, Decibel projected that AgMedica could <a href="https://www.benzinga.com/markets/cannabis/24/10/41600492/decibel-acquires-agmedica-announces-private-placement-and-third-quarter-guidance">contribute $30 million of net revenue</a> and $4 million of EBITDA in 2025, totaling an anticipated $130 million of net revenue and $25 million of adjusted EBITDA in 2025 on a pro-forma basis.
The transaction is expected to materially expand Decibel&#8217;s international footprint with EU GMP certification that enables export of flower and a variety of extract products, with proven sales to seven different countries including Australia, Denmark, Germany, Israel, Norway, Spain and the United Kingdom.
Price Action
Decibel shares closed Monday's market session 6.62% higher at $0.0499 per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42137701/canadian-cannabis-co-decibel-reports-12-yoy-drop-in-q3-revenue-but-increases-gross-margin-to-53">Canadian Cannabis Co. Decibel Reports 12% YoY Drop In Q3 Revenue But Increases Gross Margin To 53%</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/12/42280135/health-canada-cuts-14-6m-from-cannabis-program-amid-federal-austerity">Health Canada Cuts $14.6M From Cannabis Program Amid Federal Austerity</a></li>
</ul>
Photo: Courtesy of pashabo&nbsp;via Shutterstock

Cannabis

DBCCF

TSXV:DB

Decibel Receives Final TSX Venture Exchange Acceptance For AgMedica Acquisition And Debenture Conversion

Goldman Sachs analyst Gustavo Miele initiates coverage on Afya (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFYA#NASDAQ">AFYA</a>) with a Sell rating and announces Price Target of $16.

Initiation

AFYA

Goldman Sachs Initiates Coverage On Afya with Sell Rating, Announces Price Target of $16

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) with a Buy and maintains $35 price target.

ATYR

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

THE LAWSUIT: A class action securities lawsuit was filed against Metagenomi, Inc. (MGX) that seeks to recover losses of Metagenomi shareholders who...

Metagenomi, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky LLP for More Information – MGX

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Metagenomi, Inc. (MGX – Research Report) today and set a price target of $7.00. ...

Metagenomi's Advancements in SMART Platform and Robust Pipeline Justify Buy Rating

Metagenomi (MGX) presented a poster titled "Efficient and specific genome editing with metagenomics-derived base editor for human therapeutic appli...

Metagenomi presents poster on genome editing at ESGCT

Cash, cash equivalents, and available-for-sale marketable securities were $274.6M as of September 30…"Our strong pace of innovation and execution c...

Metagenomi reports Q3 EPS (51c), consensus (78c)

TD Cowen analyst Joseph Thome maintained a Buy rating on Metagenomi, Inc. (MGX – Research Report) today. The company's shares closed today at $2.11...

Metagenomi, Inc. (MGX) Receives a Buy from TD Cowen

Metagenomi, Inc. GAAP EPS of -$0.51, revenue of $11.51M

There's a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Metagenomi, Inc. (MGX – Research Report) and Kayne Anderson ...

Analysts Offer Insights on NA Companies: Metagenomi, Inc. (MGX) and Kayne Anderson BDC, Inc. (KBDC)

Metagenomi, Inc. ( ($MGX) ) has released its Q3 earnings. Here is a breakdown of the information Metagenomi, Inc. presented to its investors. Metag...

Metagenomi Reports Q3 Earnings and Strategic Progress

A&nbsp;class action&nbsp;lawsuit was filed against Metagenomi Inc. ($MGX) by Levi & Korsinsky on September 26, 2024. The plaintiffs (shareholders) ...

Class Action Lawsuit Against Metagenomi Inc. (NASDAQ:MGX)

Strong Financial Position and Promising Hemophilia A Program Bolster Metagenomi's Buy Rating

KBDC

Penny Stocks

Press Releases

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Metagenomi, Inc. (MGX)

MGX Deadline: MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit

MGX Deadline: Rosen Law Firm Urges Metagenomi, Inc. (NASDAQ: MGX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi

MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Legal

DEADLINE ALERT for BMBL, MGX, POWW, and FNA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

MGX DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important November 25 Deadline in Securities Class Action – MGX

DEADLINE ALERT for BMBL, MGX, POWW, FNA: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

MGX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Comments

Metagenomi

Metagenomi (MGX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga